Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. Eli Lilly and Company
  6. Summary
    LLY   US5324571083

ELI LILLY AND COMPANY

(LLY)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
09/20/2021 09/21/2021 09/22/2021 09/23/2021 09/24/2021 Date
231.64(c) 230.17(c) 228.3(c) 232.18(c) 231.68(c) Last
2 803 437 2 172 825 2 529 635 1 912 322 1 642 578 Volume
+0.67% -0.63% -0.81% +1.70% -0.22% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 27 278 M - -
Net income 2021 6 347 M - -
Net Debt 2021 11 480 M - -
P/E ratio 2021 33,3x
Yield 2021 1,41%
Sales 2022 28 011 M - -
Net income 2022 7 365 M - -
Net Debt 2022 10 316 M - -
P/E ratio 2022 28,1x
Yield 2022 1,57%
Capitalization 210 B 210 B -
EV / Sales 2021 8,12x
EV / Sales 2022 7,87x
Nbr of Employees 35 000
Free-Float 99,8%
More Financials
Company
Eli Lilly and Company is a drug manufacturing company. The Company discover, develop, manufacture, and market products in a human pharmaceutical product segment. The Company’s products include Diabetes and other endocrinology products, including Baqsimi, Basaglar, Forteo, Humalog, Humatrope, Humulin, Jardiance, Trajenta and Trulicity. Its Immunology products include Olumiant and Taltz. Its Neuroscience products... 
Read more
Sector
Pharmaceuticals
Calendar
09/28 | 01:20pmPresentation
More about the company
Ratings of Eli Lilly and Company
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about ELI LILLY AND COMPANY
09/24Eli Lilly and Company Issues Voluntary Nationwide Recall of One Lot of GLUCAGON® Emerge..
CI
09/24ELI LILLY AND COMPANY :  Issues Voluntary Nationwide Recall of One Lot o..
PR
09/23Lilly to Supply the EU and EEA with Up to 220,000 Doses of Bamlanivimab
CI
09/23GenEdit Inc announced that it has received $26 million in funding from a group of inves..
CI
09/21ELI LILLY AND : Sets Pricing Terms For $1.5 Billion Cash Tender Offer
MT
09/21ELI LILLY AND : to Deliver 220,000 COVID-19 Antibody Cocktail Doses to EU
MT
09/21ELI LILLY AND : Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.5 ..
PR
09/21ELI LILLY AND : Lilly Signs Pact with European Commission to Supply Bamlanivimab and Etese..
MT
09/21Eli Lilly Announces Joint Procurement Agreement with the European Commission
CI
09/21ELI LILLY AND : Signs Pact With EU Commission to Supply COVID-19 Monoclonal Antibody Treat..
MT
09/21Eli Lilly in Procurement Deal With EC to Supply Covid-19 Treatment
DJ
09/21ELI LILLY AND : Reports $2 Billion Tender Offer Results
MT
09/21ELI LILLY AND : Lilly Raises $2 Billion In Buyback Offer Of Outstanding Debt Securities
MT
09/21ELI LILLY AND : Lilly Announces the Early Tender Results of Its Pending Cash Tender Offer ..
PR
09/21Lilly Announces the Early Tender Results of Its Pending Cash Tender Offer for Up to $1...
CI
More news
News in other languages on ELI LILLY AND COMPANY
09/22ELI LILLY : contrat avec l'Europe pour un traitement du Covid
09/21Lilly signe un pacte avec la Commission européenne pour fournir du Bamlanivimab et de l..
09/21EU-Kommission unterschreibt Vertrag für weiteres Covid-19-Medikament
09/21Lilly lève 2 milliards de dollars dans le cadre d'une offre de rachat de titres de créa..
09/17MÄRKTE USA/Leichter - Zwischen China-Sorgen und "Hexensabbat"
More news
Analyst Recommendations on ELI LILLY AND COMPANY
More recommendations
Analysis
U.S. approval of Biogen Alzheimer's drug sends shares soaring, hailed as 'big day" for patients
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | LLY | US5324571083 | MarketScreener
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Last Close Price 231,68 $
Average target price 265,00 $
Spread / Average Target 14,4%
EPS Revisions
Managers and Directors
David A. Ricks Chairman, President & Chief Executive Officer
Anat Ashkenazi Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Diogo Rau Senior VP, Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
ELI LILLY AND COMPANY37.22%210 037
JOHNSON & JOHNSON4.44%432 675
ROCHE HOLDING AG10.16%321 605
PFIZER, INC.19.37%246 358
NOVO NORDISK A/S50.45%231 485
ABBVIE INC.-0.07%189 211